These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 32048240)

  • 1. Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension.
    Studer S; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
    Pulm Ther; 2020 Jun; 6(1):79-92. PubMed ID: 32048240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era.
    Zelt JGE; Sugarman J; Weatherald J; Partridge ACR; Liang JC; Swiston J; Brunner N; Chandy G; Stewart DJ; Contreras-Dominguez V; Thakrar M; Helmersen D; Varughese R; Hirani N; Umar F; Dunne R; Doyle-Cox C; Foxall J; Mielniczuk L
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34675044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline history of patients using selexipag for pulmonary arterial hypertension.
    Highland KB; Hull M; Pruett J; Elliott C; Tsang Y; Drake W
    Ther Adv Respir Dis; 2019; 13():1753466619843774. PubMed ID: 30983530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database.
    Studer S; Hull M; Pruett J; Koep E; Tsang Y; Drake W
    Pulm Circ; 2019; 9(1):2045894018816294. PubMed ID: 30421652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.
    Copher R; Cerulli A; Watkins A; Laura Monsalvo M
    J Med Econ; 2012; 15(5):947-55. PubMed ID: 22554140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and treatment patterns of disease-specific drugs among patients with pulmonary arterial hypertension: A nationwide, new-user cohort study.
    Tsai CY; Shen CW; Lai HL; Chen CY
    Front Pharmacol; 2022; 13():1030693. PubMed ID: 36712686
    [No Abstract]   [Full Text] [Related]  

  • 7. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Analysis of Treatment Patterns Among Hospitalized Patients with Pulmonary Arterial Hypertension.
    Ogbomo A; Tsang Y; Kariburyo F; Tsai WL; Panjabi S
    Pulm Ther; 2021 Dec; 7(2):575-590. PubMed ID: 34699029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.
    Burke JP; Hunsche E; Régulier E; Nagao M; Buzinec P; Drake Iii W
    Am J Manag Care; 2015 Jan; 21(3 Suppl):s47-58. PubMed ID: 25734573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using Real World Evidence to Describe Pulmonary Arterial Hypertension Treatment Patterns, Healthcare Resource Utilization, and Costs Associated with PDE-5 Inhibitor Monotherapy.
    Ruiz G; Yeaw J; Lickert CA; De AP; Wade RL; Pruett J; Drake W
    J Health Econ Outcomes Res; 2018; 5(2):206-219. PubMed ID: 35620777
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database.
    Berger A; Edelsberg J; Teal S; Mychaskiw MA; Oster G
    J Health Econ Outcomes Res; 2014; 1(3):254-265. PubMed ID: 34430662
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?
    Moonen A; Garsia R; Youssef P; Torzillo P; Corte T; Boehm C; Cordina R; Celermajer D; Lau E
    Intern Med J; 2017 Oct; 47(10):1124-1128. PubMed ID: 28560817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 'Real-World' Analysis of Persistence on and Adherence to Glipizide GITS, Glipizide IR and Glibenclamide in Managed Care among Patients with Type 2 Diabetes Mellitus.
    Hurley CR; Mishra A; Cantor SE; Nelson M; Walker AM
    Clin Drug Investig; 2002 Sep; 22(9):575-584. PubMed ID: 29492851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary hypertension: role of combination therapy.
    Meis T; Behr J
    Curr Vasc Pharmacol; 2011 Jul; 9(4):457-64. PubMed ID: 21143162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.
    Lajoie AC; Lauzière G; Lega JC; Lacasse Y; Martin S; Simard S; Bonnet S; Provencher S
    Lancet Respir Med; 2016 Apr; 4(4):291-305. PubMed ID: 26935844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension.
    van de Veerdonk MC; Huis In T Veld AE; Marcus JT; Westerhof N; Heymans MW; Bogaard HJ; Vonk-Noordegraaf A
    Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28663315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States.
    Pizzicato LN; Nadipelli VR; Governor S; Mao J; Lanes S; Butler J; Pepe RS; Phatak H; El-Kersh K
    Pulm Circ; 2022 Apr; 12(2):e12090. PubMed ID: 35795495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ESC guidelines 2015 on pulmonary hypertension].
    Olschewski H; Kovacs G; ;
    Herz; 2015 Dec; 40(8):1055-60. PubMed ID: 26626554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence and compliance among U.S. patients receiving pazopanib or sunitinib as first-line therapy for advanced renal cell carcinoma: a retrospective claims analysis.
    Byfield SA; McPheeters JT; Burton TM; Nagar SP; Hackshaw MD
    J Manag Care Spec Pharm; 2015 Jun; 21(6):515-22. PubMed ID: 26011553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
    Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
    Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.